(Q45245263)

11 December 2017

title

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers (English)

1 reference

11 December 2017

1 reference

1 reference

Thomas R MacGregor

1

1 reference

11 December 2017

John P Sabo

2

1 reference

11 December 2017

Stephen H Norris

3

1 reference

11 December 2017

Philip Johnson

4

1 reference

11 December 2017

Lawrence Galitz

5

1 reference

11 December 2017

Scott McCallister

6

1 reference

11 December 2017

publication date

1 November 2004

1 reference

11 December 2017

1 reference

11 December 2017

volume

5

1 reference

11 December 2017

issue

6

1 reference

11 December 2017

page(s)

371-382

1 reference

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Principles and practice of HIV-protease inhibitor pharmacoenhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FRRX7-49ME-27V7-MWWV

10.1310/RRX7-49ME-27V7-MWWV

21 January 2018

Identifiers

DOI

1 reference

release_w7kfdfnugvb6vhxglv5np62lpa

11 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/w7kfdfnugvb6vhxglv5np62lpa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference